Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Azeliragon · 1 trial · 1 indication
Progression-free survival (PFS) of newly diagnosed unmethylated GBM treated with the combination of RT and azeliragon.
| Arm | Type | Description |
|---|---|---|
| Daily oral azeliragon | EXPERIMENTAL | Azeliragon to be administered once daily for several days before, during, and after radiation therapy. |
| Name | Type | Description |
|---|---|---|
| Azeliragon | DRUG | Oral capsule |
Inclusion Criteria: * 1\. Histopathologically proven diagnosis of IDH-wildtype glioblastoma (GBM, WHO grade 4) according to the 2021 WHO classification (including subtypes such as gliosarcoma). 2\. Diagnosis must be established by open biopsy or tumor resection. Patients who have only had a ster...